Correction to: J Exp Clin Cancer Res 33, 55 (2014)
https://doi.org/10.1186/1756-9966-33-55
Anzeige
Following publication of the original article [1], the authors identified minor errors in image-typesetting in Fig. 2; specifically, in Fig. 2D, the ‘97-h’ panel (top left) has been replaced by the correct image.
Fig. 2
SMC4 tumor-promoting effects (× 400). A Colony formation in soft agar after exposure to SMC4-homo-830. Representative images were taken at time 72 h after transfection. B Cell growth rates after exposure to SMC4-homo-830 as detected by WST-1 assay. C Wound-healing assays and cell motility after exposure to SMC4-homo-830. Representative images were taken at time 72 h after scratching. D SMC4-homo-830 decreased tumor cell invasion activity of 97-H and HepG2 cells. (*p < 0.05)
×
The corrected figure is provided here. The corrections do not have any effect on the results or conclusions of the paper. The original article has been corrected.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.
Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.
Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
